Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom

References

• Horner MJ, Ries LAG, Krapcho M, . SEER Cancer Statistics Review 1975-2006. [Based on November 2008 SEER data submission, posted to the SEER website 2009.] Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2006/
   Google Scholar
• Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973–988.
   PubMed Web of Science ®Google Scholar
• D'Antonio J. Chronic myelogenous leukemia. Clin J Oncol Nurs 2005;9:535–538.
   PubMedGoogle Scholar
• Faderl S, Talpaz M, Estrov Z. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164–172.
   PubMed Web of Science ®Google Scholar
• Kalidas M, Kantarijan HM, Talpaz M. Chronic myelogenous leukemia. J Am Med Assoc 2001;286:895–898.
   PubMed Web of Science ®Google Scholar
• Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005;25:325–334.
   PubMed Web of Science ®Google Scholar
• Dalziel K, Round A, Stein K, . Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004;8(28).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O'Brien SG, Guilhot F, . Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Cortes JE, . Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003;97:1033–1041.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Branford S, . Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS). Blood 2010;116:3758–3765.
   PubMed Web of Science ®Google Scholar
• Kielhorn A, Graf von der Schulenburg JM. The health economics handbook. 2nd ed. Chester: Adis International; 2000.
   Google Scholar
• Morris S, Devlin N, Parkin D. Economic analysis in health care. London: Hoboken; 2007.
   Google Scholar
• Hahn EA, Glendenning GA, Sorensen MV, . Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003;21: 2138–2146.
   PubMed Web of Science ®Google Scholar
• Reed SD, Anstrom KJ, Ludmer JA, . Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574–2583.
   PubMed Web of Science ®Google Scholar
• Gordois A, Scuffham P, Warren E, . Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer 2003;89:634–640.
   PubMed Web of Science ®Google Scholar
• Warren E, Ward S, Gordois A, . Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 2004;26:1924–1933.
   PubMed Web of Science ®Google Scholar
• Szabo SM, Levy AR, Davis C, . A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health 2010;13:103–111.
   PubMed Web of Science ®Google Scholar
• McDonough CM, Tosteson AN. Measuring preferences for costutility analysis: how choice of method may influence decisionmaking. Pharmacoeconomics 2007;25:93–106.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, . Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683–690.
   PubMed Web of Science ®Google Scholar
• Levy AR, Krowdley K, Iloeje UH, . The impact of chronic hepatitis B disease progression on quality of life: a multinational study of health state preferences from infected and uninfected persons. Value Health 2008;11:527–538.
   PubMed Web of Science ®Google Scholar
• Levy AR, Christensen T, Johnson J. Utility values for symptomatic non-severe hypoglycemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008;6:73–80.
   PubMed Web of Science ®Google Scholar
• Drummond MF. Introducing economic and quality of life measures into clinical studies. Ann Med 2001;33:344–349.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt T, Zeitler H-P, Gulich M, . A comparison of different strategies to collect standard gamble utilities. Med Decision Making 2004;24:493–503.
   PubMed Web of Science ®Google Scholar
• Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002;12:160–178.
   PubMedGoogle Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–1108.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal, 2008. Available from: http://www.nice.org.uk
   Google Scholar
• Scottish Medicines Consortium. Guidance to manufacturers for completion of New Product Assessment Form (NPAF) (revised June 2010). Available from: http://www.scottishmedicines.org.uk
   Google Scholar
• Stalmeier PF, Lamers LM, Busschbach JJ, . On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences. Med Care 2007;45:835–841.
   PubMed Web of Science ®Google Scholar